Many oral targeted
Coadministration of ritonavir prolongs the serum con-centrations of nirmatrelvir to achieve the target thera-peutic effect
Overall, these findings suggest that co-administration of ritonavir-boosted drugs with DOACs may induce serious DIs owing to the simultaneous inhibition of multiple
Ritonavir boosts nirmatrelvir by inhibiting cytochrome P450 3A4 (CYP3A4), the isoenzyme primarily responsible for metabolizing several commonly prescribed medications
Ritonavir, a strong cytochrome P450 (CYP) 3A4 inhibitor and a P-glycoprotein (P-gp) inhibitor, is coadministered with nirmatrelvir to increase the blood
Ritonavir is a HIV protease inhibitor routinely prescribed to HIV patients that also potently inactivates cytochrome P4503A4 (CYP3A4), the major human drug
Recently Yu et al
drug-drug interaction RTV ritonavir P-gp P-glycoprotein RIF rifampin NFV nelfinavir P450 cytochrome P450 qd once daily MTBE methyl t-butyl ether 4-OH BUP (2011) Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir
Using an in vitro cocktail method with human liver microsomes (HLM), we observed that ritonavir strongly inhibited CYPs in the following
Other advantages of the new drug are reduced capability for adverse drug interactions, improved tolerability, and higher aqueous solubility
Nirmatrelvir/ritonavir also referred to as ritonavir-boosted nirmatrelvir, is an oral combination medication used to treat coronavirus disease 2019 (COVID-19)
John's wort
strong cytochrome P450 (CYP) 3A inhibitor, is required to increase the exposure of nirmatrelvir to a
Introduction
Of the total 57 isozymes discovered to date, 6 of these are responsible for 90%
2 of the FDA guidance for industry entitled Clinical Drug Interaction Studies — Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions (January 2020) for more As part of a larger clinical drug-drug interaction (DDI) study aimed at in vitro to in vivo prediction of HIV protease inhibitor metabolic and transporter-based DDIs, we measured the inductive (staggered administration) and inductive plus inhibitory (simultaneously administered) effect of multiple dose ritonavir (RTV), nelfinavir (NFV), or
Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications The ritonavir component boosts plasma concentrations of nirmatrelvir through the potent and rapid inhibition of the key drug-metabolizing enzyme cytochrome P450 (CYP) 3A4
Metabolism: Lopinavir/ritonavir (LPV/r) is a cytochrome P450 (CYP) 3A4 substrate and inhibitor with the potential for multiple drug interactions